Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators..

Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.

PMID:
23141816
2.

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G.

Lancet. 2009 Apr 25;373(9673):1429-39. doi: 10.1016/S0140-6736(09)60622-X. Epub 2009 Mar 28.

PMID:
19329178
3.

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.

Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua T, Ponikowski P, Severin T, Unemori E, Voors AA, Metra M.

Eur Heart J. 2014 Apr;35(16):1041-50. doi: 10.1093/eurheartj/eht497. Epub 2013 Dec 6.

4.

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators..

J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005.

5.

Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.

Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M.

J Am Coll Cardiol. 2014 Oct 14;64(15):1591-8. doi: 10.1016/j.jacc.2014.05.071.

6.

Design of the RELAXin in acute heart failure study.

Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA.

Am Heart J. 2012 Feb;163(2):149-55.e1. doi: 10.1016/j.ahj.2011.10.009.

PMID:
22305830
7.

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.

Sato N, Takahashi W, Hirayama A, Ajioka M, Takahashi N, Okishige K, Wang X, Maki A, Maruyama H, Ebinger U, Yamaguchi M, Pang Y, Matsumoto H, Kawana M.

Circ J. 2015;79(6):1237-47. doi: 10.1253/circj.CJ-15-0227. Epub 2015 Apr 24.

8.

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.

Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M.

Eur Heart J. 2014 Feb;35(7):431-41. doi: 10.1093/eurheartj/eht459. Epub 2013 Nov 18.

9.

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.

Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR.

Eur Heart J. 2013 Oct;34(40):3128-36. doi: 10.1093/eurheartj/eht371. Epub 2013 Sep 2.

10.

Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.

Cotter G, Voors AA, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Milo O, Hua TA, Qian M, Severin TM, Teerlink JR, Metra M, Davison BA.

Eur J Heart Fail. 2015 Nov;17(11):1133-43. doi: 10.1002/ejhf.331. Epub 2015 Sep 3.

11.

Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.

Ghosh RK, Banerjee K, Tummala R, Ball S, Ravakhah K, Gupta A.

Cardiovasc Ther. 2017 Feb;35(1):55-63. doi: 10.1111/1755-5922.12231. Review.

PMID:
27727514
12.

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.

Liu LC, Voors AA, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Chen Y, Greenberg BH, Ponikowski P, Pang PS, Prescott MF, Hua TA, Severin TM, Metra M.

Clin Res Cardiol. 2016 Sep;105(9):727-37. doi: 10.1007/s00392-016-0979-8. Epub 2016 Mar 26.

13.

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.

Metra M, Teerlink JR, Felker GM, Greenberg BH, Filippatos G, Ponikowski P, Teichman SL, Unemori E, Voors AA, Weatherley BD, Cotter G.

Eur J Heart Fail. 2010 Oct;12(10):1130-9. doi: 10.1093/eurjhf/hfq132. Epub 2010 Aug 22.

14.

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.

Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M; RELAX-AHF Investigators..

Eur J Heart Fail. 2014 Nov;16(11):1230-40. doi: 10.1002/ejhf.170. Epub 2014 Oct 7.

15.

Serelaxin and acute heart failure.

Tietjens J, Teerlink JR.

Heart. 2016 Jan;102(2):95-9. doi: 10.1136/heartjnl-2014-306786. Epub 2015 Nov 24. Review. Erratum in: Heart. 2016 Feb 1;102(3):253.

PMID:
26603680
16.

Serelaxin : a potential new drug for the treatment of acute heart failure.

Neverova N, Teerlink JR.

Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28. Review.

PMID:
24865798
17.

Representativeness of RELAX-AHF clinical trial population in acute heart failure.

Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF.

Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):259-68. doi: 10.1161/CIRCOUTCOMES.113.000418. Epub 2014 Mar 4.

18.

Therapeutic effects of serelaxin in acute heart failure.

Du XJ, Hewitson TD, Nguyen MN, Samuel CS.

Circ J. 2014;78(3):542-52. Epub 2014 Jan 23.

19.

Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.

Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, Greenberg BH, Filippatos G, Davison BA, Cotter G, Prescott MF, Hua TA, Lopez-Pintado S, Severin T, Metra M.

Eur J Heart Fail. 2015 Dec;17(12):1262-70. doi: 10.1002/ejhf.341. Epub 2015 Sep 3.

20.

Serelaxin a novel treatment for acute heart failure.

Castrini AI, Carubelli V, Lazzarini V, Bonadei I, Lombardi C, Metra M.

Expert Rev Clin Pharmacol. 2015;8(5):549-57. doi: 10.1586/17512433.2015.1073587. Review.

PMID:
26294074

Supplemental Content

Support Center